baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Editas Medicine/ US28106W1036 /

2024-05-03 9:59:50 PM	Chg. +0.04	Volume	Bid-	Ask-	High	Low
5.67USD	+0.71%	16,971 Turnover: 96,659.45	-Bid Size: -	-Ask Size: -	5.95	5.65

GlobeNewswire 05-02 Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

GlobeNewswire 05-01 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

GlobeNewswire 04-22 Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline...

GlobeNewswire 04-08 Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

GlobeNewswire 03-29 SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

GlobeNewswire 03-20 Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

GlobeNewswire 02-28 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

GlobeNewswire 02-21 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Inv...

GlobeNewswire 01-31 Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire 01-08 Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan H...

GlobeNewswire 01-03 Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-13 Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

GlobeNewswire 2023-12-11 Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at t...

GlobeNewswire 2023-11-07 Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire 2023-11-03 Editas Medicine Announces Third Quarter 2023 Results and Business Updates

GlobeNewswire 2023-11-02 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 202...

GlobeNewswire 2023-10-27 Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

GlobeNewswire 2023-10-16 Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 f...

GlobeNewswire 2023-09-25 Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

GlobeNewswire 2023-09-25 Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Co...

GlobeNewswire 2023-08-30 Editas Medicine Announces Upcoming Investor Events

GlobeNewswire 2023-08-28 APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

GlobeNewswire 2023-08-28 Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

GlobeNewswire 2022-03-09 TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities

GlobeNewswire 2022-02-28 Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent ...

Editas Medicine/ US28106W1036 /

If you wish to receive reply to your feedback, please provide your email address.